Modality
Radioligand
MOA
FGFRi
Target
SGLT2
Pathway
Autophagy
DLBCL
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
Jan 2024
→ May 2027
Phase 2Current
NCT04858091
1,652 pts·DLBCL
2024-01→2027-05·Not yet recruiting
1,652 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-05-151.1y awayPh3 Readout· DLBCL
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2027-05-15 · 1.1y away
DLBCL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04858091 | Phase 2/3 | DLBCL | Not yet recr... | 1652 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 |